Voyager Therapeutics Inc (VYGR)
7.91
+0.05
(+0.64%)
USD |
NASDAQ |
Jun 28, 16:00
7.89
-0.02
(-0.25%)
After-Hours: 20:00
Voyager Therapeutics Research and Development Expense (TTM): 100.70M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 100.70M |
| December 31, 2023 | 92.17M |
| September 30, 2023 | 80.97M |
| June 30, 2023 | 74.44M |
| March 31, 2023 | 64.98M |
| December 31, 2022 | 60.76M |
| September 30, 2022 | 60.23M |
| June 30, 2022 | 58.81M |
| March 31, 2022 | 65.79M |
| December 31, 2021 | 73.78M |
| September 30, 2021 | 81.76M |
| June 30, 2021 | 88.89M |
| March 31, 2021 | 98.80M |
| December 31, 2020 | 108.75M |
| September 30, 2020 | 123.31M |
| June 30, 2020 | 128.04M |
| March 31, 2020 | 127.20M |
| December 31, 2019 | 119.74M |
| Date | Value |
|---|---|
| September 30, 2019 | 100.10M |
| June 30, 2019 | 86.95M |
| March 31, 2019 | 74.88M |
| December 31, 2018 | 64.91M |
| September 30, 2018 | 61.32M |
| June 30, 2018 | 64.25M |
| March 31, 2018 | 63.04M |
| December 31, 2017 | 62.26M |
| September 30, 2017 | 61.66M |
| June 30, 2017 | 52.40M |
| March 31, 2017 | 47.59M |
| December 31, 2016 | 42.25M |
| September 30, 2016 | 38.74M |
| June 30, 2016 | 34.92M |
| March 31, 2016 | 30.89M |
| December 31, 2015 | 27.68M |
| September 30, 2015 | 21.42M |
| June 30, 2015 | 17.34M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
58.81M
Minimum
Jun 2022
128.04M
Maximum
Jun 2020
89.96M
Average
88.89M
Median
Jun 2021
Research and Development Expense (TTM) Benchmarks
| Ligand Pharmaceuticals Inc | 23.84M |
| Durect Corp | 24.88M |
| Stereotaxis Inc | 9.77M |
| Agios Pharmaceuticals Inc | 296.84M |
| Cara Therapeutics Inc | 106.14M |